Company DescriptionTong Ren Tang Technologies Co. Ltd. manufactures and sells Chinese medicine products in Mainland China and Hong Kong. The company also cultivates, purchases, and sells Chinese medicinal raw materials; produces and sells ointment, tea drinks, and foot care products; sells medicinal products; and provides medical research and development, advertisement, and Chinese medical consultation and treatment services. In addition, it is involved in the technological development and sale of biological products, Chinese and Western medicines, cosmetics, and healthcare products; wholesale and retail sale of Chinese medicines and healthcare products; and internal and external surgery, medical examination, and hospital management activities. Further, it produces and processes biochemical products; extracts and processes plants; and produces food and daily chemical products, and medical services. The company was founded in 1669 and is based in Beijing, the People's Republic of China.

How the Company Makes Money

Tong Ren Tang Technologies Co Financial Statement Overview

Summary

Tong Ren Tang Technologies Co is in good financial health, with strong revenue growth and a solid balance sheet. However, declining net profit margins and lack of recent cash flow data could pose future challenges. The company should address profitability and cash flow management to maintain its financial stability.

Income Statement

Positive

Tong Ren Tang Technologies Co has demonstrated a strong revenue growth trend over the years, with a 7.17% increase from 2022 to 2023 and a 7.18% increase from 2023 to 2024. The Gross Profit Margin for 2024 is approximately 39.64%, which is robust for the industry. However, the Net Profit Margin decreased from 8.71% in 2023 to 7.19% in 2024, indicating a decline in profitability. EBIT and EBITDA margins are stable, suggesting operational efficiency.

Balance Sheet

Very Positive

The company maintains a strong financial position with a Debt-to-Equity Ratio of 0.34 in 2024, indicating low leverage and financial stability. The Return on Equity (ROE) for 2024 stands at 7.24%, which is reasonable. The Equity Ratio is high at 50%, reflecting a solid capital structure with a significant portion of assets funded by equity.

Cash Flow

Positive

The Cash Flow statement shows inconsistency, with no Free Cash Flow reported for 2024, which may indicate cash management issues. Historically, Operating Cash Flow has been positive, but the lack of data for 2024 raises concerns. The company should focus on ensuring consistent cash flow to support operations and growth.

Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Breakdown
Income Statement		Total Revenue
7.26B	6.77B	5.99B	5.40B	4.61B
	Gross Profit
2.88B	2.85B	2.59B	2.29B	2.07B
	EBIT
985.16M	1.12B	1.21B	1.08B	943.55M
	EBITDA
1.17B	1.30B	1.39B	1.26B	1.14B
	Net Income Common Stockholders
521.79M	590.19M	582.89M	507.25M	467.55M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
4.38B	4.24B	4.18B	3.89B	3.49B
	Total Assets
14.41B	13.51B	12.48B	11.59B	10.94B
	Total Debt
2.43B	1.63B	1.59B	1.64B	1.69B
	Net Debt
-1.70B	-1.12B	-2.13B	-1.60B	-1.26B
	Total Liabilities
4.24B	3.86B	3.47B	3.44B	3.19B
	Stockholders Equity
7.21B	6.89B	6.48B	5.98B	5.73B
Cash Flow		Free Cash Flow
-158.56M	450.78M	565.85M	877.01M	-110.09M
	Operating Cash Flow
15.61M	554.17M	723.77M	1.03B	435.81M
	Investing Cash Flow
0.00	-1.07B	43.01M	-197.36M	-195.44M
	Financing Cash Flow
288.35M	-497.76M	-499.45M	-474.67M	-164.51M

Tong Ren Tang Technologies Co Peers Comparison

Overall Rating

UnderperformOutperform

Sector (54)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TGRNF		$836.02M	11.52	7.39%	3.88%	―	―
Sector *	54 Neutral	$5.31B	3.29	-45.39%	2.79%	16.77%	-0.07%
SBMFF		$10.37B	42.63	6.14%	1.32%	―	―
CHJTF		$12.99B	16.93	13.20%	4.42%	―	―
SFOSF		$8.54B	12.84	6.22%	1.96%	―	―
640		€3.76B	8.39		3.02%	―	―
2877	77 Outperform	HK$5.65B	6.20	11.61%	7.77%	-18.09%	-15.08%

* Healthcare Sector Average

Performance Comparison

TGRNF

Tong Ren Tang Technologies Co

0.65

-0.06

-8.45%

SBMFF

Sino Biopharmaceutical

0.58

0.21

56.76%

CHJTF

CSPC Pharmaceutical Group

0.87

0.01

1.16%

SFOSF

Shanghai Fosun Pharmaceutical (Group) Co

1.96

0.14

7.69%

DE:640

China Resources Pharmaceutical Group Ltd.

0.58

-0.09

-13.43%

HK:2877

China Shineway Pharmaceutical Group Limited

7.48

-0.06

-0.80%

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.